| HOME >> BIOLOGY >> TECHNOLOGY |
"Atritech has developed an exciting new product that in our opinion will offer a significant clinical benefit to the market. We look forward to working with the company to help make the WATCHMAN a commercial success," commented Pete McNerney, Partner at Thomas, McNerney & Partners.
"We are excited to have attracted a new lead investor along with receiving the continued support from our existing investor group prior to the upcoming FDA panel meeting. After nine years in the development and clinical stage, we are ready to present our case to the FDA and launch commercial operations outside the United States," said Jim Bullock, President & CEO of Atritech. "We also look forward to the presentation of the PROTECT AF trial results this weekend at the ACC. Our results would be of significant interest to any patient with atrial fibrillation currently on warfarin therapy." added Bullock.
The PROTECT AF results will be unveiled at the Late Breaking Clinical Trial session during the I2 Summit Scientific Meeting at 8:30 am on March 28, 2009. The I2 Summit is part of the Annual Meeting of the American College of Cardiology being held March 28 - 31 in Orlando, Florida. The Company will also be exhibiting at booth #2857.
About Atritech
Atritech is privately held and based in Plymouth, Minnesota. Major investors in Atritech include SplitRock Partners, Prism Venture Partners, Thomas McNerney Partners, Tullis-Dickerson Partners, The Vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more information, visit www.atritech.net.
About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management, focused on investing in life
'/>"/>
| SOURCE Atritech, Inc. Copyright©2009 PR Newswire. All rights reserved |